Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the first quarter of 2014, including revenue from sales of Iclusig (ponatinib) and licensing agreements. The Company also provided an update on corporate developments. Total revenue for the quarter ended March 31, 2014 was $11.8 million, which includes product revenue from sales of Iclusig and license revenue. Net loss for the quarter ended March 31, 2014 was $49.8 million, or $0.27 per share, compared to net loss of $64.7 million, or $0.36 per share, for the same period in 2013. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is -10.83%. On last trading day company shares ended up $6.67. Analysts mean target price for the company is $9.06. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -13.62%.
Arena Pharmaceuticals Inc (NASDAQ:ARNA) Director Donald Belcher sold 4,176 shares of the company’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $7.00, for a total value of $29,232.00. Following the sale, the director now directly owns 68,728 shares of the company’s stock, valued at approximately $481,096. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares advanced 1.90% in last trading session and ended the day on $6.98. ARNA Gross Margin is 92.40% and its return on assets is -6.80%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly performance is 20.14 %.
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) reported Q1 EPS of ($0.15), $0.07 worse than the analy t estimate of ($0.08). Revenue for the quarter came in at $10 million versus the consensus estimate of $9.91 million. At March 31, 2014, the Company had cash, cash equivalents, short-term investments and interest receivable of $155.1 million, as compared to $55.7 million at December 31, 2013. Keryx Biopharmaceuticals (NASDAQ:KERX) shares moved down -13.72 % in last trading session and was closed at $12.26, while trading in range of $ 12.11 – 13.19 -. Keryx Biopharmaceuticals (NASDAQ:KERX) year to date (YTD) performance is -5.33 %.
Gilead Sciences, Inc. (NASDAQ:GILD), the maker of a hepatitis C treatment projected to be the best-selling drug of all time, said it would double the size of an existing $5 billion share buyback program. With the new $5 billion pool, the biotechnology drug company has $7.9 billion to repurchase some of its $121.1 billion in outstanding shares. The company’s stock has fallen below its 52-week high of $83.95 after criticism of the $1,000-per-pill price of the hepatitis C treatment, called Sovaldi. Gilead Sciences, Inc. (NASDAQ:GILD) ended the last trading day at $78.73. Company weekly volatility is calculated as 3.20% and price to cash ratio as 17.65. Gilead Sciences, Inc. (NASDAQ:GILD) showed a negative weekly performance of -0.37%.